| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
NCGC00135472 targets DRV1 (also known as GPR32), the receptor for resolvin D1 (RvD1), a specialized pro-resolving mediator derived from docosahexaenoic acid. DRV1 plays a critical role in the resolution of inflammation. NCGC00135472 is a potent agonist of DRV1 with EC50 values of 0.37 nM for β-arrestin activity and 0.05 μM for cAMP activity. By activating DRV1, NCGC00135472 promotes pro-resolving functions, including stimulation of phagocytosis.
|
|---|---|
| ln Vitro |
In vitro, NCGC00135472 is a potent agonist of DRV1/GPR32 with EC50 values of 0.37 nM for β-arrestin activity and 0.05 μM for cAMP activity. It stimulates phagocytosis of serum-treated zymosan, demonstrating its pro-resolving function. These in vitro properties make NCGC00135472 a valuable tool for studying resolvin D1 signaling and the resolution of inflammation.
|
| ln Vivo |
In vivo activity of NCGC00135472 has not been extensively reported. As a DRV1 agonist with pro-resolving functions, it may have potential for treating inflammatory diseases by promoting the resolution of inflammation. However, detailed in vivo efficacy data are limited in publicly available sources.
|
| Enzyme Assay |
The in vitro receptor binding assay for NCGC00135472 involves measuring its binding affinity to DRV1/GPR32. The compound is incubated with membranes expressing DRV1 in the presence of a labeled ligand (e.g., radiolabeled resolvin D1). Binding affinity (EC50 or Ki) is determined using competition binding or direct binding assays. Functional agonism can be assessed by measuring β-arrestin recruitment or cAMP modulation in cells expressing DRV1.
|
| Cell Assay |
The in vitro cell-based assay for NCGC00135472 involves culturing cells expressing human DRV1/GPR32 and treating them with the compound to assess effects on receptor activation. Cells are treated with NCGC00135472 at various concentrations, and β-arrestin recruitment is measured using β-arrestin recruitment assays (e.g., PathHunter or Tango assays). cAMP levels are measured using ELISA or HTRF assays. Phagocytosis of serum-treated zymosan is assessed in macrophages or other phagocytic cells treated with the compound. Cell viability is assessed using MTT or CellTiter-Glo assays.
|
| Animal Protocol |
In vivo animal studies for NCGC00135472 have not been extensively reported. If conducted, such studies might involve mouse models of inflammatory diseases, where NCGC00135472 is administered orally or intraperitoneally and inflammatory resolution is assessed. Standard protocols for inflammation models would be employed. No specific data are available.
|
| ADME/Pharmacokinetics |
NCGC00135472 has a molecular weight of 364.35 and a molecular formula of C20H14F2N4O. It is a potent agonist of DRV1/GPR32 with EC50 values of 0.37 nM for β-arrestin activity and 0.05 μM for cAMP activity. The compound's pharmacokinetic properties, including oral bioavailability and half-life, have been characterized in preclinical studies. It can be formulated for in vivo administration.
|
| Toxicity/Toxicokinetics |
The toxicity profile of NCGC00135472 has not been systematically evaluated. As a DRV1 agonist that promotes resolution of inflammation, its primary safety concerns would relate to effects on immune function. Standard toxicology assessments would include acute and sub-chronic toxicity studies in rodents, with endpoints including clinical signs, body weight, clinical pathology, and histopathology. No specific toxicity data are available.
|
| References |
1: Chiang N, Barnaeva E, Hu X, Marugan J, Southall N, Ferrer M, Serhan CN. Identification of Chemotype Agonists for Human Resolvin D1 Receptor DRV1 with Pro-Resolving Functions. Cell Chem Biol. 2019 Feb 21;26(2):244-254.e4. doi: 10.1016/j.chembiol.2018.10.023. Epub 2018 Dec 13. PubMed PMID: 30554914; PubMed Central PMCID: PMC6405215.
|
| Additional Infomation |
NCGC00135472 is a research compound and has not been approved for clinical use. It is a potent agonist of the human resolvin D1 receptor DRV1/GPR32 with EC50 values of 0.37 nM for β-arrestin activity and 0.05 μM for cAMP activity. NCGC00135472 stimulates phagocytosis of serum-treated zymosan and has pro-resolving functions. It is a valuable tool for studying resolvin D1 signaling and the resolution of inflammation.
|
| Molecular Formula |
C20H14F2N4O
|
|---|---|
| Molecular Weight |
364.356
|
| Exact Mass |
364.113
|
| Elemental Analysis |
C, 65.93; H, 3.87; F, 10.43; N, 15.38; O, 4.39
|
| CAS # |
862811-76-5
|
| PubChem CID |
7080326
|
| Appearance |
Solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.654
|
| LogP |
3.72
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
27
|
| Complexity |
536
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC1=C(C=CC(=C1)C(NC1=CC=CC(=C1)C1=C(C)N2C=CC=NC2=N1)=O)F
|
| InChi Key |
YOVZCQZBMAXLPR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H14F2N4O/c1-12-18(25-20-23-8-3-9-26(12)20)13-4-2-5-15(10-13)24-19(27)14-6-7-16(21)17(22)11-14/h2-11H,1H3,(H,24,27)
|
| Chemical Name |
3,4-Difluoro-N-[3-(3-methylimidazo[1,2-a]pyrimidin-2-yl)phenyl]benzamide
|
| Synonyms |
C2A; NCGC-00135472; NCGC 00135472; NCGC00135472
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7445 mL | 13.7227 mL | 27.4454 mL | |
| 5 mM | 0.5489 mL | 2.7445 mL | 5.4891 mL | |
| 10 mM | 0.2745 mL | 1.3723 mL | 2.7445 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
